AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05788510 — intervention group
Intervention type: OTHER
Intervention: Pneumococcal vaccine
Description: Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
Study NCT05791981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony & Health Intervention
Description: Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study
Study NCT05791981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
Study NCT05791981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
Study NCT06572865 — intervention group
Intervention type: OTHER
Intervention: Screening for depression and anxiety
Description: Parents respond to questionnaires assessing depression and anxiety.
Study NCT06459479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational Artificial Intelligence Simulations
Description: Use of Conversational Artificial Intelligence Simulations generate medical scenario.
Study NCT04696380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL e-cigarette
Description: Participants will sample preferred vs non-preferred JUUL flavors.
Study NCT04613362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENACITY Telehealth Cognitive Behavioral Therapy for Migraine
Description: Clinical health psychology therapy delivered via telehealth
Study NCT04613362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Usual Care
Description: Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
Study NCT05413590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires completion
Description: Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
Study NCT05413590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric forces
Description: Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
Study NCT05413590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy cost
Description: Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
Study NCT05427344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exercise group
Description: Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
Study NCT05427344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land exercise group
Description: Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
Study NCT05427344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group who will not perform additional physical activity or receive any extra treatments.
Study NCT05682170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5 ZN-c3
Description: Oral agent
Study NCT05682170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Oral agent
Study NCT05484102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk fermented with lactobacillus paracasei CBA L74
Description: milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
Study NCT05484102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo milk formula
Description: placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
Study NCT05577754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib (BYL719)
Description: Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
Study NCT05577754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib (BYL719)
Description: Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
Study NCT05577754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
Study NCT05577754 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Optional lumbar puncture + blood sample
Description: Between 6 and 24 months of treatment with Alpelisib
Study NCT05577754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional lumbar puncture + blood sample
Description: Between 6 and 24 months of treatment with Alpelisib
Study NCT06389526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHS-1000
Description: Specified dose on specified days
Study NCT06389526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days
Study NCT06095986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
Study NCT06095986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
Study NCT04733326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
Study NCT04733326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
Study NCT04733326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
Study NCT04790188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nootropic
Description: 10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
Study NCT04790188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nootropic
Description: 10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
Study NCT04790188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10g of maltodextrin lemon flavor (HSN®).
Study NCT04790188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrin lemon flavor (HSN®).
Study NCT05189275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.
Study NCT05189275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.
Study NCT06491186 — intervention group
Intervention type: OTHER
Intervention: Point of Care Ultrasound
Description: Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
Study NCT05301959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low intensity percutaneous musculoskeletal electrolysis
Description: An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
Study NCT05301959 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham application
Description: A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
Study NCT05301959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silbernagel protocol
Description: The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
Study NCT05301959 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Silbernagel protocol
Description: The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
Study NCT05182086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group physical therapy and dietary improvements
Description: 20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
Study NCT06247124 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multi-channel communication campaign to promote HPV vaccination
Description: High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
Study NCT05524025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary TTMV-HPV DNA Test
Description: Mouthwash rinse
Study NCT05524025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood TTMV-HPV DNA Test
Description: Blood test
Study NCT04913454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40 Hz multi-sensory (auditory + visual) stimulation and cognitive training
Description: 40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
Study NCT04913454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
Study NCT06521086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Supplements - Fresubin KCAL Drinks
Description: Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
Study NCT05562791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Study NCT05839015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention Based on Self-Compassion
Description: Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
Study NCT05562791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Study NCT04934748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study NCT04934748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study NCT05255679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early FES
Description: FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
Study NCT05255679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed FES
Description: FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
Study NCT05688059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorbable Suture and Permanent Suture
Description: Absorbable Suture and Permanent Suture
Study NCT05408338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Meal
Description: Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)
Study NCT05408338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Added Sugar Meal
Description: Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
Study NCT05005260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
Study NCT05005260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
Description: Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
Study NCT05602493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludronate®
Description: In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
Study NCT05602493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: sterile saline
Study NCT05236270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Study NCT05236270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Study NCT05236270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Educational Message with Tailored Questions/Prompts
Description: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
Study NCT06560203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Description: Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
Study NCT05108870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201
Description: A anti-cancer vaccine that treats HPV-related cancers.
Study NCT05108870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202
Description: A anti-cancer vaccine that treats HPV-related cancers.
Study NCT05108870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy drug.
Study NCT05108870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy drug.
Study NCT05108870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.